Enovis Corp (ENOV) - Total Liabilities
Based on the latest financial reports, Enovis Corp (ENOV) has total liabilities worth $2.34 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Enovis Corp (ENOV) cash flow conversion to assess how effectively this company generates cash.
Enovis Corp - Total Liabilities Trend (2004–2025)
This chart illustrates how Enovis Corp's total liabilities have evolved over time, based on quarterly financial data. Check ENOV asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Enovis Corp Competitors by Total Liabilities
The table below lists competitors of Enovis Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥3.56 Billion |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
India | Rs1.96 Billion |
|
Kelt Exploration Ltd.
TO:KEL
|
Canada | CA$477.39 Million |
|
Happy Forgings Limited
NSE:HAPPYFORGE
|
India | Rs3.41 Billion |
|
Home First Finance Company India Limited
NSE:HOMEFIRST
|
India | Rs100.87 Billion |
|
Shanghai Chengdi Constr Co
SHG:603887
|
China | CN¥9.64 Billion |
|
One Software Technologies Ltd
TA:ONE
|
Israel | ILA1.47 Billion |
|
Chongqing Department Store Co Ltd
SHG:600729
|
China | CN¥11.41 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Enovis Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Enovis Corp market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enovis Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enovis Corp (2004–2025)
The table below shows the annual total liabilities of Enovis Corp from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.34 Billion | +8.74% |
| 2024-12-31 | $2.15 Billion | +97.90% |
| 2023-12-31 | $1.09 Billion | +32.20% |
| 2022-12-31 | $823.45 Million | -78.64% |
| 2021-12-31 | $3.85 Billion | +2.41% |
| 2020-12-31 | $3.76 Billion | -3.43% |
| 2019-12-31 | $3.90 Billion | +24.63% |
| 2018-12-31 | $3.13 Billion | +4.43% |
| 2017-12-31 | $2.99 Billion | -9.04% |
| 2016-12-31 | $3.29 Billion | -5.30% |
| 2015-12-31 | $3.48 Billion | -10.69% |
| 2014-12-31 | $3.89 Billion | +1.33% |
| 2013-12-31 | $3.84 Billion | -3.31% |
| 2012-12-31 | $3.97 Billion | +341.85% |
| 2011-12-31 | $899.27 Million | +11.61% |
| 2010-12-31 | $805.71 Million | +0.17% |
| 2009-12-31 | $804.30 Million | +7.79% |
| 2008-12-31 | $746.14 Million | -11.54% |
| 2007-12-31 | $843.49 Million | +6.59% |
| 2006-12-31 | $791.33 Million | +11.75% |
| 2005-12-31 | $708.15 Million | +16.13% |
| 2004-12-31 | $609.79 Million | -- |
About Enovis Corp
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more